Alle Storys
Folgen
Keine Story von Korian Deutschland AG mehr verpassen.

Korian Deutschland AG

euro adhoc: Curanum AG
Quarterly or Semiannual Financial Statements
CURANUM Increases EBITDA Margin to 14.3% in Second Quarter of 2005

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
11.08.2005
In the first quarter of 2005 CURANUM AG, Munich, increased its sales
revenue from EUR 46.4 m to a total of EUR 47.4 m. In the entire first
half of the year proceeds grew by almost 5% to reach a total of EUR
93.6 m (previous year EUR 89.2 m). Thanks to the increase in
occupancy and increases in the calculation of investment costs the
Munich operator of senior citizens and nursing care centers was even
able to increase its sales with 150 beds less than in the previous
year. Overall proceeds from nursing care and service rose to a total
of EUR 84.1 m (compared with EUR 79.9 m in the previous year), the
apartment division with out-patient services amounted to EUR 5.7 m as
in the previous year and other revenues accounted for EUR 3.8 m
(previous year: EUR 3.5 m) of sales revenues.
The CURANUM Group achieved a result before interest, taxes,
depreciation and amortization (EBITDA) of EUR 6.8 m (previous year:
EUR 5.5 m) in the second quarter of 2005 alone, so that the EBITDA
margin rose to 14.3%. The EBIT margin also developed quite positively
in the three months from April 1 to June 30: the net yield ratio for
the operating result increased from 9.4% in the second quarter of
2004 to 12.2% in the second quarter of 2005.
The result after taxes (net profit) climbed in the second quarter
from EUR 1.9 m to EUR 2.5 m, almost reaching the peak of the entire
half-year result of the previous year. Earnings per share (EPS)
increased to EUR 0.09, following EUR 0.06 in the second quarter of
the previous year.
In the first half of 2005 CURANUM AG achieved a result before
interest, taxes, depreciation and amortization of  EUR12.7 m
(previous year: EUR 10.2 m), which corresponds to a EBITDA margin of
13.6%. The operating result (EBIT) improved from EUR 7.6 m to EUR 9.8
m, while the prior-tax result rose by 63% to EUR 6.7 m (previous
year: EUR 4.1 m). CURANUM AG concluded the first half of the year
with a net profit for the period of EUR4.2m (previous year: EUR2.6m),
while earnings per share improved from EUR 0.09 to EUR 0.14 at the
end of the period under review.
As a consequence of these good results we are planning to achieve
sales revenue in the amount of EUR 187.8 m for the entire year of
2005 - in accordance with International Financial Reporting Standards
(IFRS) - and EUR 25.6 m in terms of our EBITDA, as well as a result
after taxes of EUR 8.5 m.
Munich, August 11, 2005
The Board of Management
in EUR m             Q2 - 2005 Q2 - 2004 to previous year:
Sales revenue      47.4      46.4      2.2%
Personnel costs    24.0      23.5      2.1%
Rental expense     7.0       8.2       -14.6%
EBITDA             6.8       5.5       23.6%
in % of sales      14.3%     11.9%
Depreciation       1.1       1.1       0.0%
EBIT               5.8       4.4       31.8%
in % of sales      12.2%     9.5%
Financial result   -1.8      -1.7      5.9%
EBT                4.0       2.6       53.8%
Net profit         2.5       1.9       31.6%
EPS (EUR)            0.09      0.06      50.0%
~
in EUR m             HY1 - 2005 HY1 - 2004 over previous year
Sales revenue      93.6       89.2       4.9%
Personnel costs    47.4       45.8       3.5%
Rental expense     15.7       16.0       -1.9%
EBITDA             12.7       10.2       24.5%
in % of sales      13.6%      11.4%
Depreciation       2.9        2.6        11.5%
EBIT               9.8        7.6        28.9%
in % of sales      10.5%      8.5%
Financial result   -3.1       -3.5       -11.4%
EBT                6.7        4.1        63.4%
Net profit         4.2        2.6        61.5%
EPS (EUR)            0.14       0.09       55.6%
end of announcement                               euro adhoc 11.08.2005 10:16:50

Further inquiry note:

Bernd Rothe
Tel.: +49 (0)89 242065-60
E-Mail: bernd.rothe@curanum.de

Branche: Healthcare Providers
ISIN: DE0005240709
WKN: 524070
Index: Prime Standard, CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Bayerische Börse / regulated dealing
Berliner Wertpapierbörse / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bremer Wertpapierbörse (BWB) / free trade

Weitere Storys: Korian Deutschland AG
Weitere Storys: Korian Deutschland AG